Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer

20260 citationsJournal Articlegold Open Access

Authors

François Ghiringhelli · Centre Georges François Leclerc

R. Kim · Moffitt Cancer Center

T. Macarulla · Vall d'Hebron Hospital Universitari

I. Moreno · Hospital Universitario HM Sanchinarro

A.R. Abdul Razak · University Health Network

Jordi Rodon Ahnert · The University of Texas MD Anderson Cancer Center

Chih‐Yi Liao

Abstract

Dual PD-1/TIM-3 inhibition was tolerable but exhibited modest antitumor activity in patients with advanced/metastatic recurrent BTC who had not received prior anti-PD-(L)1 treatment.

Topics & Keywords

Galectins and Cancer Biology Peptidase Inhibition and Analysis IgG4-Related and Inflammatory Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 14, Issue 3, pp. e012344-e012344

DOI: 10.1136/jitc-2025-012344

Field-Weighted Citation Impact: 0.00